Zentalis Pharmaceuticals (ZNTL) Interest & Investment Income (2019 - 2026)

Zentalis Pharmaceuticals' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 198.76% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $21.5 million, a 277.43% increase from a year earlier, with the FY2025 full-year figure at $16.2 million, down 36.52% from the prior year.
• Interest & Investment Income steadied at $2.6 million in Q1 2026 per ZNTL's latest filing, from $2.6 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $34.9 million in Q1 2024 and bottomed at -$22.9 million in Q2 2024.
• The 5-year median for Interest & Investment Income is $3.2 million (2022), against an average of $4.3 million.
• Across the five-year window, Interest & Investment Income surged 3572.73% in 2022 and slumped 613.66% in 2024, its largest moves.
• Year by year, Interest & Investment Income stood at $3.2 million in 2022, then surged by 111.88% to $6.8 million in 2023, then tumbled by 68.28% to $2.2 million in 2024, then rose by 20.58% to $2.6 million in 2025, then climbed by 0.15% to $2.6 million in 2026.
• Per Business Quant, the three latest ZNTL Interest & Investment Income figures stand at $2.6 million (Q1 2026), $2.6 million (Q4 2025), and $7.0 million (Q3 2025).